WallStSmart

Tenet Healthcare Corporation (THC)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 111% more annual revenue ($45.20B vs $21.45B). TMO leads profitability with a 15.1% profit margin vs 7.9%. TMO appears more attractively valued with a PEG of 1.56. THC earns a higher WallStSmart Score of 66/100 (B-).

THC

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 6/9Altman Z: 1.69

TMO

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 4.0Quality: 5.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

THCUndervalued (+78.8%)

Margin of Safety

+78.8%

Fair Value

$1068.55

Current Price

$190.38

$878.17 discount

UndervaluedFair: $1068.55Overvalued
TMOSignificantly Overvalued (-16.1%)

Margin of Safety

-16.1%

Fair Value

$408.60

Current Price

$465.00

$56.40 premium

UndervaluedFair: $408.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

THC4 strengths · Avg: 9.5/10
P/E RatioValuation
10.1x10/10

Attractively priced relative to earnings

Return on EquityProfitability
30.3%10/10

Every $100 of equity generates 30 in profit

EPS GrowthGrowth
87.6%10/10

Earnings expanding 87.6% YoY

Free Cash FlowQuality
$1.46B8/10

Generating 1.5B in free cash flow

TMO1 strengths · Avg: 9.0/10
Market CapQuality
$176.32B9/10

Large-cap with strong market position

Areas to Watch

THC4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.8%4/10

2.8% revenue growth

Altman Z-ScoreHealth
1.694/10

Distress zone — elevated risk

Profit MarginProfitability
7.9%3/10

7.9% margin — thin

PEG RatioValuation
4.802/10

Expensive relative to growth rate

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

P/E RatioValuation
26.1x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : THC

The strongest argument for THC centers on P/E Ratio, Return on Equity, EPS Growth.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap. Profitability is solid with margins at 15.1% and operating margin at 17.9%.

Bear Case : THC

The primary concerns for THC are Revenue Growth, Altman Z-Score, Profit Margin.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

THC profiles as a value stock while TMO is a mature play — different risk/reward profiles.

THC carries more volatility with a beta of 1.30 — expect wider price swings.

TMO is growing revenue faster at 6.2% — sustainability is the question.

THC generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

THC scores higher overall (66/100 vs 62/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Tenet Healthcare Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Tenet Healthcare Corporation is a diversified health services company. The company is headquartered in Dallas, Texas.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?